StreetInsider.com News Articles

TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana

Wed, 23 Sep 2026 03:05:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a major U.S. health insurer.

About TempraMed Technologies Ltd.

TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops

TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana

Wed, 23 Sep 2026 03:05:00 -0400

About TempraMed Technologies Ltd.

TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana

Wed, 23 Sep 2026 03:05:00 -0400

About TempraMed Technologies Ltd.

TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana

Wed, 23 Sep 2026 03:05:00 -0400

About TempraMed Technologies Ltd.

TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue

Fri, 18 Sep 2026 16:45:00 -0400

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025

Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance.

The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in TempraMed's history. August 2026 sales reached approximately US$403,000, representing the Company's second-highest

TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue

Fri, 18 Sep 2026 16:45:00 -0400

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025

TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue

Fri, 18 Sep 2026 16:45:00 -0400

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025

TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue

Fri, 18 Sep 2026 16:45:00 -0400

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025

TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece

Tue, 01 Sep 2026 06:45:00 -0400

Distribution framework pairs TempraMed's injectable medication-protection products with one of the largest, most established Greek pharmacy and healthcare distributors

Highlights:

LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Greece brings an established pharmacy division, local distribution infrastructure and experience representing international healthcare and consumer brands.
Adding and renewing

TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece

Tue, 01 Sep 2026 06:45:00 -0400

Distribution framework pairs TempraMed's injectable medication-protection products with one of the largest, most established Greek pharmacy and healthcare distributors
Highlights:
LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Greece brings an established pharmacy division, local distribution infrastructure and experience representing international healthcare and consumer brands.
Adding and renewing

TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece

Tue, 01 Sep 2026 06:45:00 -0400

Distribution framework pairs TempraMed's injectable medication-protection products with one of the largest, most established Greek pharmacy and healthcare distributors
Highlights:
LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Greece brings an established pharmacy division, local distribution infrastructure and experience representing international healthcare and consumer brands.
Adding and renewing

TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece

Tue, 01 Sep 2026 06:45:00 -0400

Distribution framework pairs TempraMed's injectable medication-protection products with one of the largest, most established Greek pharmacy and healthcare distributors
Highlights:
LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Greece brings an established pharmacy division, local distribution infrastructure and experience representing international healthcare and consumer brands.
Adding and renewing

TempraMed signs $3.8M Saudi distribution deal for VIVI Cap

Tue, 25 Aug 2026 07:02:17 -0400

TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) announced it signed a five-year distribution agreement on August 10, 2026 with Black Olives Company for the commercialization of a private-label version of its VIVI Cap product in Saudi Arabia.

The agreement targets rollout through the pharmacy network of Nahdi Medical Company, which the company describes as Saudi Arabia's largest pharmacy chain, operating more than 1,100 locations across the country.

Under the terms of the agreement, the distributor is required to issue an initial purchase order for 10,000 units upon execution. Payment of 60% of that order becomes due following receipt of applicable

TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap

Tue, 25 Aug 2026 07:00:00 -0400

Agreement targets commercialization through the physical retail network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain.
Highlights
Five-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order.
Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain.
TempraMed believes the private-label structure can improve in-store commitment, pharmacist engagement and consumer promotion as the product is expected to be positioned as part of Nahdi's own retail offering.
Commercial launch is subject to applicable Saudi regulatory clearance, after

TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap

Tue, 25 Aug 2026 07:00:00 -0400

Agreement targets commercialization through the physical retail network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain.
Highlights
Five-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order.
Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain.
TempraMed believes the private-label structure can improve in-store commitment, pharmacist engagement and consumer promotion as the product is expected to be positioned as part of Nahdi's own retail offering.
Commercial launch is subject to applicable Saudi regulatory clearance, after

TempraMed Announces Extension of Maccabi Healthcare Services Agreement

Thu, 20 Aug 2026 07:00:00 -0400

Maccabi exercises option to extend agreement for an additional year, reinforcing continued adoption of TempraMed's medication protection technology
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year under the same terms. For more information on the Company's agreement with Maccabi, please refer to its press release dated December 8, 2025.
Maccabi

TempraMed Announces Extension of Maccabi Healthcare Services Agreement

Thu, 20 Aug 2026 07:00:00 -0400

Maccabi exercises option to extend agreement for an additional year, reinforcing continued adoption of TempraMed's medication protection technology
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year under the same terms. For more information on the Company's agreement with Maccabi, please refer to its press release dated December 8, 2025.
Maccabi

TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies

Tue, 18 Aug 2026 07:00:00 -0400

Agreement transitions previously announced LOI into a definitive commercial relationship
First bulk commercial order fulfilled for distribution into clinics and pharmacies
TempraMed expands access to its temperature-protection solutions through healthcare channels in Panama
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed is pleased to announce that it has entered into a definitive exclusive distribution agreement (the "Agreement") with TEM Consulting International S.A. ("TEM") a leading healthcare

TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies

Tue, 18 Aug 2026 07:00:00 -0400

Agreement transitions previously announced LOI into a definitive commercial relationship
First bulk commercial order fulfilled for distribution into clinics and pharmacies
TempraMed expands access to its temperature-protection solutions through healthcare channels in Panama
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed is pleased to announce that it has entered into a definitive exclusive distribution agreement (the "Agreement") with TEM Consulting International S.A. ("TEM") a leading healthcare

TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors

Thu, 30 Jul 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares are also now DTC eligible, significantly enhancing the accessibility and efficiency of trading for U.S. investors.
TempraMed common shares trade on the OTCQB under the symbol TMPTF while continuing to trade on the Canadian Securities Exchange ("CSE") under the symbol VIVI.
The Company's OTCQB uplisting, combined with DTC eligibility, represents an important milestone in expanding TempraMed's

TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors

Thu, 30 Jul 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares are also now DTC eligible, significantly enhancing the accessibility and efficiency of trading for U.S. investors.
TempraMed common shares trade on the OTCQB under the symbol TMPTF while continuing to trade on the Canadian Securities Exchange ("CSE") under the symbol VIVI.
The Company's OTCQB uplisting, combined with DTC eligibility, represents an important milestone in expanding TempraMed's